An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

[1]  Q. Tao,et al.  USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5 , 2019, The Journal of Biological Chemistry.

[2]  M. Fischer,et al.  Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface. , 2019, Cancer research.

[3]  R. C. Poulos,et al.  JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma , 2019, Nature Communications.

[4]  A. Kundaje,et al.  The ENCODE Blacklist: Identification of Problematic Regions of the Genome , 2019, Scientific Reports.

[5]  Wenjing Zhang,et al.  Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer , 2019, Journal of experimental & clinical cancer research : CR.

[6]  R. C. Poulos,et al.  Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. , 2018, Cancer cell.

[7]  F. Westermann,et al.  TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets , 2018, Nature Communications.

[8]  F. Speleman,et al.  Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. , 2018, Cancer research.

[9]  Stuart A. Wilson,et al.  Co-transcriptional Loading of RNA Export Factors Shapes the Human Transcriptome , 2018, bioRxiv.

[10]  S. Shieh,et al.  Deubiquitinating enzyme USP3 controls CHK1 chromatin association and activation , 2018, Proceedings of the National Academy of Sciences.

[11]  Giovanna Ambrosini,et al.  PWMScan: a fast tool for scanning entire genomes with a position-specific weight matrix , 2018, Bioinform..

[12]  D. Rickman,et al.  The Expanding World of N-MYC-Driven Tumors. , 2018, Cancer discovery.

[13]  Donald R. Polaski,et al.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.

[14]  Huan Wang,et al.  USP3 stabilizes p53 protein through its deubiquitinase activity. , 2017, Biochemical and biophysical research communications.

[15]  Guohui Li,et al.  ALYREF mainly binds to the 5′ and the 3′ regions of the mRNA in vivo , 2017, Nucleic acids research.

[16]  M. Eilers,et al.  Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors , 2016, Proceedings of the National Academy of Sciences.

[17]  G. Qing,et al.  Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. , 2016, Molecular cell.

[18]  A. Califano,et al.  HAUSP deubiquitinated and stabilizes N-Myc in neuroblastoma , 2016, Nature Medicine.

[19]  F. Speleman,et al.  Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma , 2015, Science Translational Medicine.

[20]  Qi Sun,et al.  Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. , 2015, Molecular cell.

[21]  G. Perini,et al.  Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma , 2015, Oncotarget.

[22]  J. Schulte,et al.  IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Wenwei Zhang,et al.  An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era , 2014, Genome Biology.

[24]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[25]  Erin F. Simonds,et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.

[26]  David P. Kreil,et al.  A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control consortium , 2014, Nature Biotechnology.

[27]  David P. Kreil,et al.  The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance , 2014, Nature Biotechnology.

[28]  F. Berthold,et al.  Chromosome 17/17q gain and unaltered profiles in high resolution array‐CGH are prognostically informative in neuroblastoma , 2014, Genes, chromosomes & cancer.

[29]  David P. Kreil,et al.  Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures , 2014, Nature Communications.

[30]  Y. Nakamura,et al.  RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma , 2014, Oncogene.

[31]  Yinyin Li,et al.  USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors , 2013, Cell Research.

[32]  F. Westermann,et al.  Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma , 2013, Cell Death and Disease.

[33]  K. Uzawa,et al.  ALY as a potential contributor to metastasis in human oral squamous cell carcinoma , 2013, Journal of Cancer Research and Clinical Oncology.

[34]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[35]  A. Fullaondo,et al.  The Nuclear Protein ALY Binds to and Modulates the Activity of Transcription Factor E2F2* , 2013, Molecular & Cellular Proteomics.

[36]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[37]  R. Versteeg,et al.  Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. , 2011, Endocrine-related cancer.

[38]  A. Biankin,et al.  SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability , 2011, PLoS genetics.

[39]  R. Luna,et al.  Differential expression of THOC1 and ALY mRNP biogenesis/export factors in human cancers , 2011, BMC Cancer.

[40]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[41]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[42]  R. Bayliss,et al.  Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. , 2010, The Biochemical journal.

[43]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[44]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[45]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[46]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[47]  M. Okada,et al.  Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY , 2008, Proceedings of the National Academy of Sciences.

[48]  A. Iavarone,et al.  The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein , 2008, Nature Cell Biology.

[49]  S. Elledge,et al.  The ubiquitin-specific protease USP28 is required for MYC stability , 2007, Nature Cell Biology.

[50]  J. Dudley,et al.  ALY Is a Common Coactivator of RUNX1 and c-Myb on the Type B Leukemogenic VirusEnhancer , 2007, Journal of Virology.

[51]  M. Cole,et al.  A Conserved Myc Protein Domain, MBIV, Regulates DNA Binding, Apoptosis, Transformation, and G2 Arrest , 2006, Molecular and Cellular Biology.

[52]  K. Helin,et al.  The Ubiquitin Ligase HectH9 Regulates Transcriptional Activation by Myc and Is Essential for Tumor Cell Proliferation , 2005, Cell.

[53]  F. Berthold,et al.  Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  S. Kim,et al.  Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.

[55]  Akira Nakagawara,et al.  PPM1D is a potential target for 17q gain in neuroblastoma. , 2003, Cancer research.

[56]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[57]  Kevin Struhl,et al.  TREX is a conserved complex coupling transcription with messenger RNA export , 2002, Nature.

[58]  M. Schwab,et al.  MYCN amplification and 17q in neuroblastoma: Evidence for structural association , 2001, Genes, chromosomes & cancer.

[59]  M. Ohira,et al.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma , 2000, Oncogene.

[60]  P. Kogner,et al.  Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24 , 1999, British Journal of Cancer.

[61]  M. Green,et al.  A human nuclear-localized chaperone that regulates dimerization, DNA binding, and transcriptional activity of bZIP proteins. , 1999, Molecular cell.

[62]  F. Speleman,et al.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. , 1999, The New England journal of medicine.

[63]  I. Lewis,et al.  Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. , 1997, European journal of cancer.

[64]  J. Maris,et al.  Biology and genetics of human neuroblastomas. , 1997, Journal of pediatric hematology/oncology.

[65]  R Grosschedl,et al.  ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. , 1997, Genes & development.

[66]  H. Caron,et al.  Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. , 1995, Medical and pediatric oncology.

[67]  H. Weintraub,et al.  Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.

[68]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[69]  J. Trent,et al.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour , 1983, Nature.

[70]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[71]  K. Helin,et al.  The Ubiquitin Ligase HectH 9 Regulates Transcriptional Activation by Myc and Is Essential for Tumor Cell Proliferation , 2017 .

[72]  S. Robinson,et al.  Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. , 2016, Cancer cell.

[73]  K. Zaret,et al.  Sequential chromatin immunoprecipitation from animal tissues. , 2004, Methods in enzymology.

[74]  Kevin Struhl,et al.  Quantitative sequential chromatin immunoprecipitation, a method for analyzing co-occupancy of proteins at genomic regions in vivo. , 2004, Nucleic acids research.

[75]  K. Matthay,et al.  Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. , 1997, The American journal of pathology.

[76]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[77]  A. Ciechanover,et al.  Degradation of MYCN oncoprotein by the ubiquitin system. , 1991, Progress in clinical and biological research.